Jounce therapeutics is a differentiated player in the hot immuno-oncology sector.
JNCE stock has not been fairly priced after its newly struck partnership with Gilead Sciences, making it a compelling buy for the short term.
JNCE's drug discovery engine continues to impress, potentially making it an equally compelling pick for the longer term.
Jounce Therapeutics (JNCE) is a small biotechnology company focused on the rapidly expanding industry of immuno-oncology. Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a